Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms

Journal of the Pediatric Infectious Diseases Society
Pranita D Tamma, Alice J Hsu

Abstract

With the current carbapenem-resistant organism crisis, conventional approaches to optimizing pharmacokinetic-pharmacodynamic parameters are frequently inadequate, and traditional salvage agents (eg, colistin, tigecycline, etc) confer high toxicity and/or have low efficacy. However, several β-lactam agents with activity against carbapenem-resistant organisms were approved recently by the US Food and Drug Administration, and more are anticipated to be approved in the near future. The primary goal of this review is to assist infectious disease practitioners with preferentially selecting 1 agent over another when treating patients infected with a carbapenem-resistant organism. However, resistance to some of these antibiotics has already developed. Antibiotic stewardship programs can ensure that they are reserved for situations in which other options are lacking and are paramount for the survival of these agents.

References

Jul 17, 2007·Clinical Microbiology Reviews·Anne Marie Queenan, Karen Bush
Nov 3, 2010·Antimicrobial Agents and Chemotherapy·David M LivermoreNeil Woodford
Jun 19, 2013·Antimicrobial Agents and Chemotherapy·Andrew P TomarasDavid P Nicolau
Apr 22, 2014·Nature·Dijun DuBen F Luisi
Feb 12, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Joseph SolomkinChristian Eckmann
Mar 18, 2015·Journal of Medicinal Chemistry·Scott J HeckerMichael N Dudley
Apr 13, 2015·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·I Olsen
May 13, 2015·Antimicrobial Agents and Chemotherapy·Douglas J BiedenbachPatricia A Bradford
May 28, 2015·Antimicrobial Agents and Chemotherapy·Amabel LapueblaJohn Quale
Jul 22, 2015·Antimicrobial Agents and Chemotherapy·Romney M HumphriesAric Gregson
Oct 6, 2015·JAMA : the Journal of the American Medical Association·Alice Y GuhAlexander J Kallen
Feb 26, 2016·Journal of Clinical Microbiology·Thomas J GniadekPatricia J Simner
Mar 11, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John E MazuskiJan Pachl
May 4, 2016·Antimicrobial Agents and Chemotherapy·Tsukasa Ito-HoriyamaKazuhiro Tateda
Jun 18, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Florian M WagenlehnerLeanne B Gasink
Jul 16, 2016·Open Forum Infectious Diseases·Latania K Logan, Robert A Bonomo
Aug 10, 2016·Antimicrobial Agents and Chemotherapy·Christopher LucastiAmanda Paschke
Oct 22, 2016·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Lindsey M WeinerDawn M Sievert
Sep 15, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ryan K ShieldsM Hong Nguyen
Dec 6, 2016·Expert Review of Anti-infective Therapy·Kevin Escandón-VargasMaría Virginia Villegas
Dec 26, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Pranita D TammaPatricia J Simner

❮ Previous
Next ❯

Citations

May 30, 2019·Antimicrobial Agents and Chemotherapy·Pranita D TammaPatricia J Simner
Aug 6, 2019·International Journal of Urology : Official Journal of the Japanese Urological Association·Hiroyuki KitanoAkio Matsubara
Dec 18, 2019·Antimicrobial Agents and Chemotherapy·David Aguilera-AlonsoFernando Baquero-Artigao
Feb 14, 2020·Journal of Clinical Microbiology·Eric RansomMaria Karlsson
Feb 8, 2020·The Pediatric Infectious Disease Journal·Leah MolloyJocelyn Y Ang
Nov 13, 2020·Clinical Microbiology Reviews·Dafna YahavLeonard Leibovici
Dec 17, 2020·Antibiotics·Laura Butragueño-LaisecaMaría José Santiago
Feb 18, 2021·Journal of the Pediatric Infectious Diseases Society·Jeffrey S GerberUNKNOWN AAP Committee on Infectious Diseases and Pediatric Infectious Diseases Society
May 30, 2021·Journal of Global Antimicrobial Resistance·Carlos D GrasaFernando Baquero-Artigao
Jul 3, 2021·Life·Roberto GiurazzaEmanuele Durante-Mangoni
Oct 31, 2021·European Journal of Hospital Pharmacy. Science and Practice·Ana Pelaez BejaranoFrancisco Javier Martínez-Marcos
Dec 30, 2020·Pediatrics·Jeffrey S GerberUNKNOWN COMMITTEE ON INFECTIOUS DISEASES, PEDIATRIC INFECTIOUS DISEASES SOCIETY
Jan 29, 2022·Seminars in Respiratory and Critical Care Medicine·Matteo BassettiAntonio Vena

❮ Previous
Next ❯

Related Concepts

Related Feeds

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Related Papers

The Journal of Hospital Infection
A P R Wilson
The Lancet Infectious Diseases
James S Soothill, Paul E Lock
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Yohei Doi
The Lancet Infectious Diseases
Sang Hee LeeSun-Shin Cha
© 2022 Meta ULC. All rights reserved